The global antibody discovery market is experiencing steady expansion as demand for advanced biologics continues to rise. According to The Insight Partners report, the market size is projected to surge from US$ 2.94 billion in 2022 to US$ 4.92 billion by 2030, registering a CAGR of 6.7% during the forecast period 2022–2030.

This growth is primarily driven by the increasing prevalence of chronic diseases, rising demand for personalized medicine, and significant technological advancements in antibody discovery platforms.

Market Overview and Key Drivers

The expansion of the biopharmaceutical industry, with its strong focus on biologics, has substantially increased the demand for antibody research services. Growing collaborations between industry players and academic institutions are facilitating resource sharing and accelerating the antibody discovery process. Additionally, the shift toward patient-centered drug development and personalized medicine is further boosting the market.

Technological advancements such as high-throughput screening, phage display, and next-generation sequencing have significantly improved the efficiency and speed of antibody discovery. Increased funding from government organizations and private companies for research and development activities is also playing a crucial role in spurring innovation in this space.

Download the free sample report here: https://www.theinsightpartners.com/sample/TIPRE00007411

Increasing Investments in Research & Development Propel Market Growth

Antibodies are extensively used in academic, research, and pharmaceutical organizations for drug and biomarker development. Small and medium-sized companies are consistently raising their R&D investments. For instance, in April 2020, the US federal government allocated US$ 3.5 billion to the Biomedical Advanced Research and Development Authority (BARDA) under the CARES Act. In September 2022, Abzena announced plans to expand its R&D capabilities in Cambridge for rapid antibody discovery.

These investments are enabling the development of better treatment options for various diseases, thereby driving the antibody discovery market forward.

Segmental Analysis

By Antibody Type The market is segmented into monoclonal antibodies, polyclonal antibodies, and others. The monoclonal antibodies segment held the largest market share of 82.6% in 2022 and is anticipated to register the highest CAGR of 6.9% during 2022–2030. Monoclonal antibodies are widely used in cancer therapy and other therapeutic areas due to their high specificity. Blockbuster drugs such as Avastin, Herceptin, Remicade, and Rituxan have significantly contributed to the acceptance of mAb therapies.

By Nature The market is divided into human and humanized, chimeric, and murine antibodies. The human and humanized segment held the largest share in 2022 and is expected to witness the fastest growth at a CAGR of 7.1% over the forecast period. These antibodies offer higher specificity, stability, and reduced immunogenicity, making them highly preferred in clinical applications.

By Service Phage display, hybridoma, transgenic animal, single cell, and yeast display are the major service segments. The phage display segment dominated with a 35.8% market share in 2022 and is projected to register the highest CAGR of 7.3% during the forecast period. Its advantages in terms of speed, simplicity, and cost-effectiveness make it a preferred technology for in vitro antibody selection.

By End User The pharmaceutical and biotechnology companies segment held the largest share in 2022 and is anticipated to grow at the fastest CAGR of 7.2% during 2022–2030. These companies drive demand due to their focus on drug discovery, proteomics, genomics, and development of targeted therapies for cancer, HIV/AIDS, and other diseases.

Regional Outlook

North America dominated the global antibody discovery market with a 44.2% share in 2022, valued at US$ 1.29 billion. The region is expected to reach US$ 2.20 billion by 2030, growing at a CAGR of 6.8%. Strong presence of the antibody research industry, technological advancements, and high cancer prevalence are key contributing factors. The United States is projected to grow at a CAGR of 7.1%.

Asia Pacific is poised to be the fastest-growing region, registering a CAGR of 7.3% over the forecast period. China held the largest share in the region in 2022, while India is expected to show significant growth. The shift in China’s biopharmaceutical industry toward innovation, along with increased government funding and research centers, is fueling regional growth.

Key Players and Recent Developments

The competitive landscape features prominent companies including:

• Charles River Laboratories International Inc.
• Sartorius AG
• Creative Biolabs Inc.
• Twist Bioscience Corp.
• Biocytogen Pharmaceuticals Beijing Co Ltd.
• Evotec SE
• Aragen Life Sciences Ltd.
• Bruker Cellular Analysis Inc.
• BioDuro LLC
• NanoCellect Biomedical Inc.

Recent notable developments include:

• Biocytogen Pharmaceuticals launched RenBiologics in January 2024 for its antibody discovery business.
• Biocytogen signed an antibody evaluation agreement with Ona Therapeutics in December 2023.
• Evotec SE collaborated with Janssen Pharmaceutica NV in June 2022.
• Sartorius AG partnered with McMaster University in August 2021 for antibody manufacturing process improvements.

About The Insight Partners

The Insight Partners delivers market intelligence and consulting services to help clients make informed decisions. The firm covers industries such as Aerospace and Defense, Automotive and Transportation, Semiconductor and Electronics, Biotechnology, Healthcare IT, Manufacturing, Medical Devices, Technology, Media, and Chemicals and Materials.

Contact Us

Email: sales@theinsightpartners.com

Website: www.theinsightpartners.com

Phone: +1-646-491-9876